Double accreditation for Myeloma UK patient services

In the last couple of months, Myeloma UK has received two professional accreditations for their patient services. In November, the Myeloma Information Specialist Team received the Helplines Standard accreditation from The Helplines Partnership for the sixteenth year running. The Helplines Standard is a nationally recognized quality standard which defines and recognizes best practice in helpline…

Details

Selinexor combination is effective for the treatment of relapsed or refractory myeloma

Results from a phase III clinical trial (BOSTON) evaluating selinexor (Xpovio®) in combination with bortezomib (Velcade®) and dexamethasone for the treatment of relapsed or refractory myeloma patients have been published in the Lancet. The data provide evidence to support the use of selinexor for the treatment of relapsed or refractory myeloma patients who had received…

Details

Myeloma and COVID-19 virtual educational resources for healthcare professionals 

During the COVID-19 pandemic, healthcare professionals looking after myeloma patients face important and difficult decisions about the best way to treat their patients, whilst minimising their risk of infection. Several myeloma specialists have been sharing their experience as they work together to consider the safest and most effective ways to manage this vulnerable group of patients. Here we have compiled a short list of informative webinars, podcasts and articles to keep…

Details